By Mill Chart
Last update: Sep 22, 2023
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) was identified as an affordable growth stock by our stock screener. NYSE:NVO is showing great growth, but also scores well on profitability, solvency and liquidity. At the same time it seems to be priced reasonably. We'll explore this a bit deeper below.
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NYSE:NVO scores a 8 out of 10:
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NYSE:NVO has achieved a 8 out of 10:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NYSE:NVO, the assigned 7 for health provides valuable insights:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:NVO, the assigned 9 is noteworthy for profitability:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
For an up to date full fundamental analysis you can check the fundamental report of NVO
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (12/8/2023, 7:07:33 PM)Premarket: 96.5 -0.14 (-0.14%)
Investors have fretted that weight loss drugs were going to overhaul the eating behaviors of consumers, health needs, and even wardrobes. So far, the fears have been overblown.
Novo Nordisk's corporate structure has a few quirks that investors need to know about.
Novo Nordisk was the talk of the pharma and medical world this year — and also the world of People magazine and E! with stars from Amy Schumer to Elon Musk using the firm’s diabetes and weight-loss medicines, Ozempic and Wegovy. This is partly why Novo Nordisk is Yahoo Finance's 2023 Company of the Year.
Nowadays, it's good to be a developer of next-generation weight loss drugs.
These drugs address a rapidly growing market.
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.
A peer-reviewed study shows a higher patient adherence rate for Novo Nordisk's (NVO) new anti-obesity drug Wegovy compared to older weight loss drugs. Read more here.
Law firms are seeking to consolidate lawsuits related to side effects of GLP-1 class of drugs filed against Novo Nordisk (NVO) and Eli Lilly (LLY). Read more here.
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news.
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer, as well as an industry leader that could struggle to meet Wall Street's lofty expectations.
The technical analysis for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is highly positive, with a rating of 10 out of 10, suggesting a potential breakout.
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.